LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
Index 615NS.SeeNodular sclerosis (NS)
NSAID.SeeNonsteroidal
anti-inflammatory drugs
(NSAID)
NSCLC.SeeNon-small cell lung
cancers (NSCLC)
NSGCT.SeeNonseminomatous
germ cell tumor (NSGCT)
Nuclear factor-kappa B (NF-kB),
422
Nuclear factor (NF), 41, 54
Nucleophosmin 1 (NPM1), 442,
448
Nucleotide excision repair (NER),
11, 12
Obesity
colon cancer risk and, 62, 68
defined, 61, 66
endometrial cancer and, 62, 68,
320, 327
kidney cancer and, 62, 68
postmenopausal breast cancer
and, 62, 68
Oblimersen, 126, 131
Occupational therapy, 573, 577
Octreotide, 553, 557
Ocular melanoma, first metastatic
site for, 376, 380
Odds ratio (OR), 242
OER.SeeOxygen enhancement
ratio (OER)
Oligodendroglioma, 384, 388,
392
Oncologic emergencies, 503–508
Oncologic surgery, anesthetics in,
80, 83
Oncology
imaging role in, 177
research, patient-reported
outcomes in, 116, 119–120
Oncology drugs, FDA approval of,
584, 587
OncotypeDX assay and breast
cancer, 336, 345
Ondansetron, for nausea
prophylaxis, 526, 532
Oophorectomy, 333, 342
Opioid analgesics, nausea and
vomiting by, 563, 568
Opioids, for bone pain from
prostate cancer, 564, 569
Opisthorchis viverrini, 258, 285,
293
Opsoclonus-myoclonus, 524
OR.SeeOdds ratio (OR)
Oral cavity cancer and smokeless
tobacco, 34, 44
Oral contraceptives and ovarian
cancer, 308, 311, 312Oral vancomycin, inC. difficile
colitis, 542, 547
Orbital tumors, 409
Oropharyngeal cancers and HPV,
39, 51
Oropharyngeal HSV, 543, 549
Orphan Drug Act of 1983, 582,
586
OS.SeeOverall survival (OS)
Osteoarthropathy, 484
Osteoblastic bone metastases, 23,
31
Osteoporosis and androgen
ablation, 293
Osteosarcoma
and other tumors, distinction
between, 400, 410
treatment modalities for, 400, 410
treatment of, 368, 373
Ovarian cancer
BAX overexpression in, 307, 312
BRCA mutation and, 137,
139–140
BRCA1 mutation and, 305, 311,
480
BSO in, 152, 158
CA-125 in, 306, 311, 314
clinical surveillance of, 310, 314
CT in, 168, 181
endometrial cancer and, 309, 313
endometrioid variants and, 309,
314
germ cell tumors and, 309, 313
granulosa cell tumors, 313
hormonal therapy for, 307, 312
immunostains on, 309, 314
Lynch syndrome and, 153, 159
MRI in, 168, 181
mucinous tumor and, 309, 314
multiparity and, 306, 312
oral contraceptives and, 308, 311,
312
ovary removal and, 311
peritoneal carcinomatosis and,
487
platinum-based chemotherapy for,
308, 309, 312, 314
prophylactic oophorectomy and,
480
PTEN mutations in, 307, 312
relapse of, 308, 312–313
risk factors for, 306, 312
sex cord–stromal tumors and, 313
surgical staging series, 311
TP53 mutation in, 307, 312
transvaginal ultrasound in, 311
ultrasound in, 168, 181
Overall survival (OS), 334, 343,
467Overdiagnosis bias, 141, 145
Oxaliplatin, 125, 131, 234
Oxygen enhancement ratio (OER),
87, 91–92p53
degradation, 14
genomic stability in, 6
mutations of, 4, 11
point mutation, in esophagus
cancer, 237
protein, characteristics of, 36,
46–47
reestablishment of, 6
PA.SeePosteroanterior (PA)
Pachydermoperiostosis
and SCLC, 519, 523
Paclitaxel, 87, 92, 372
for NSCLC treatment, 206, 211
Paget’s disease, 338, 347
Pain
chronic, management of, 563, 569
control of, 574, 577–578
Palliative care services, 562,
567–568
Palliative surgery, for gastric outlet
obstruction, 77, 81
Palmar-plantar erythrodysesthesia,
555, 559
Pancreatic cancer
ABO blood group and, 246, 251
African American men and, 243,
247
BRCA2 and, 246, 251
CA 19-9 and, 243, 247
CHRNA3 gene and, 73, 76
cigarette smoking and, 243, 247
cirrhosis and, 243, 247
endoscopic ultrasound of, 249
FOLFIRINOX in, 245, 250–251
FOLFOX6 and, 246, 251
gemcitabine and erlotinib
combination therapy in,
245, 250
gemcitabine in, 87, 92
K-ras oncogene and, 243, 248
laparoscopy and multiphase CT
of, 244, 248–249
PanIN and, 243, 247–248
p16-mediated CDK inhibition,
246, 251
risk factors for, 243, 246, 247,
251
telomere shortening, 246, 251
TGF-expression in, 246, 251
tobacco use and, 34, 44
TP53 gene mutation in, 251
Pancreatic endocrine tumors, 356,
363